BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urwyler SA, Blum CA, Coslovsky M, Mueller B, Schuetz P, Christ-Crain M. Cytokines and Cortisol - predictors of treatment response to corticosteroids in community-acquired pneumonia? J Intern Med 2019;286:75-87. [PMID: 30873676 DOI: 10.1111/joim.12891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Viasus D, Simonetti AF, Estupiñan-Bohórquez AF, Carratalà J. Effects of age and comorbidities on serum levels of inflammatory markers in community-acquired pneumonia. Eur J Clin Invest 2021;51:e13480. [PMID: 33350464 DOI: 10.1111/eci.13480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wittermans E, van der Zee PA, Qi H, van de Garde EMW, Blum CA, Christ-Crain M, Gommers D, Grutters JC, Voorn GP, Bos WJW, Endeman H. Community-acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies. ERJ Open Res 2022;8:00489-2021. [PMID: 35036417 DOI: 10.1183/23120541.00489-2021] [Reference Citation Analysis]
3 Wittermans E, Vestjens SMT, Spoorenberg SMC, Blok WL, Grutters JC, Janssen R, Rijkers GT, Smeenk FWJM, Voorn GP, van de Garde EMW, Bos WJW; Santeon-CAP Study Group., Members of the Santeon-CAP Study Group. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J 2021;58:2002535. [PMID: 33446608 DOI: 10.1183/13993003.02535-2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Qi K, Yan Z, Cheng H, Chen W, Wang Y, Wang X, Cao J, Zhang H, Sang W, Zhu F, Sun H, Li D, Wu Q, Qiao J, Fu C, Zeng L, Li Z, Zheng J, Xu K. An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. Front Oncol 2021;11:691064. [PMID: 34195092 DOI: 10.3389/fonc.2021.691064] [Reference Citation Analysis]
5 Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J. Role of the inflammatory response in community-acquired pneumonia: clinical implications. Expert Rev Anti Infect Ther 2021;:1-14. [PMID: 33034228 DOI: 10.1080/14787210.2021.1834848] [Reference Citation Analysis]
6 Méndez R, Aldás I, Menéndez R. Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). J Clin Med 2020;9:E549. [PMID: 32085380 DOI: 10.3390/jcm9020549] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kukhon FR, Festic E. Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article. Med Sci (Basel) 2021;9:34. [PMID: 34071031 DOI: 10.3390/medsci9020034] [Reference Citation Analysis]
8 Ceccato A, Russo A, Barbeta E, Oscanoa P, Tiseo G, Gabarrus A, Di Giannatale P, Nogas S, Cilloniz C, Menichetti F, Ferrer M, Niederman M, Falcone M, Torres A. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. Crit Care 2021;25:432. [PMID: 34915895 DOI: 10.1186/s13054-021-03840-x] [Reference Citation Analysis]
9 Wittermans E, van de Garde EM, Voorn GP, Aldenkamp AF, Janssen R, Grutters JC, Bos WJW; Santeon-CAP study group. Neutrophil count, lymphocyte count and neutrophil-to-lymphocyte ratio in relation to response to adjunctive dexamethasone treatment in community-acquired pneumonia. Eur J Intern Med 2021:S0953-6205(21)00371-X. [PMID: 34782191 DOI: 10.1016/j.ejim.2021.10.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]